Circulation. 2021 Oct 12;144(15):e238-e250. doi: 10.1161/CIR.0000000000001016. Epub 2021 Sep 10.
Among the estimated 6.2 million Americans living with heart failure (HF), ≈5%/y may progress to advanced, or stage D, disease. Advanced HF has a high morbidity and mortality, such that early recognition of this condition is important to optimize care. Delayed referral or lack of referral in patients who are likely to derive benefit from an advanced HF evaluation can have important adverse consequences for patients and their families. A 2-step process can be used by practitioners when considering referral of a patient with advanced HF for consideration of advanced therapies, focused on recognizing the clinical clues associated with stage D HF and assessing potential benefits of referral to an advanced HF center. Although patients are often referred to an advanced HF center to undergo evaluation for advanced therapies such as heart transplantation or implantation of a left ventricular assist device, there are other reasons to refer, including access to the infrastructure and multidisciplinary team of the advanced HF center that offers a broad range of expertise. The intent of this statement is to provide a framework for practitioners and health systems to help identify and refer patients with HF who are most likely to derive benefit from referral to an advanced HF center.
在估计有 620 万心力衰竭(HF)患者中,约有 5%/年可能进展为晚期或 D 期疾病。晚期 HF 发病率和死亡率较高,因此早期识别这种情况对于优化治疗非常重要。对于可能从晚期 HF 评估中获益的患者,如果延迟或缺乏转诊,可能会对患者及其家属产生重要的不良后果。临床医生在考虑将晚期 HF 患者转诊以考虑进行高级治疗时,可以使用两步流程,重点是识别与 D 期 HF 相关的临床线索,并评估转诊到高级 HF 中心的潜在益处。尽管患者经常被转诊到高级 HF 中心接受心脏移植或左心室辅助装置植入等高级治疗的评估,但还有其他转诊的原因,包括获得高级 HF 中心基础设施和多学科团队的机会,该团队提供广泛的专业知识。本声明的目的是为临床医生和医疗系统提供一个框架,以帮助识别和转诊最有可能从转诊到高级 HF 中心获益的 HF 患者。